Oasmia Pharmaceutical AB (OASMY PINK) stock market data APIs
$0.0402
0(0%)
as of March 14, 2025
Oasmia Pharmaceutical AB Financial Data Overview
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Prev. Close
0.0402
Open
0.0402
High
0.0402
Low
0.0402
52 wk Range
0.02-0.05
Market Cap
12 254 K
Shares Outstanding
179 M
Revenue
6 612 K
Beta
0.823
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oasmia Pharmaceutical AB data using free add-ons & libraries
Get Oasmia Pharmaceutical AB Fundamental Data
Oasmia Pharmaceutical AB Fundamental data includes:
- Net Revenue: 6 612 K
- EBITDA: -51 067 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-20
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oasmia Pharmaceutical AB News
New
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...
Oasmia Pharmaceutical AB to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 19, 2021 / Oasmia Pharmaceutical AB (STO:OASM) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 19, 2021 ...
Oasmia Pharmaceutical AB to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 19, 2021 / Oasmia Pharmaceutical AB (STO:OASM) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 19, 2021 ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
